Two large studies published in the Journal of the American Medical Association (JAMA) detail the increased cardiovascular risks including stroke and heart attack associated with taking the diabetes drug Avandia (rosiglitazone). One of the studies was led by Dr. David Graham of the FDA.
Leave a Reply